Oppenheimer set a $176.00 target price on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Thursday, TipRanks reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Other analysts also recently issued research reports about the company. Barclays lifted their target price on Jazz Pharmaceuticals from $164.00 to $180.00 and gave the company an overweight rating in a research note on Wednesday, August 7th. Royal Bank of Canada set a $184.00 target price on Jazz Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, July 3rd. Piper Jaffray Companies downgraded Jazz Pharmaceuticals from an overweight rating to a neutral rating and cut their target price for the company from $205.00 to $142.00 in a research note on Wednesday, August 21st. HC Wainwright reaffirmed a hold rating and set a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Finally, BidaskClub downgraded Jazz Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, September 7th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the stock. Jazz Pharmaceuticals has an average rating of Hold and an average price target of $168.43.
Jazz Pharmaceuticals stock traded up $0.88 during mid-day trading on Thursday, hitting $128.14. 256,169 shares of the company’s stock traded hands, compared to its average volume of 558,802. The firm has a 50 day moving average price of $130.16 and a 200 day moving average price of $134.46. The company has a quick ratio of 3.52, a current ratio of 3.71 and a debt-to-equity ratio of 0.58. The company has a market cap of $7.21 billion, a PE ratio of 10.47, a price-to-earnings-growth ratio of 1.58 and a beta of 1.10. Jazz Pharmaceuticals has a one year low of $113.52 and a one year high of $169.82.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.16 by $0.49. The firm had revenue of $534.13 million for the quarter, compared to the consensus estimate of $507.23 million. Jazz Pharmaceuticals had a return on equity of 27.72% and a net margin of 32.99%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.49 EPS. On average, analysts expect that Jazz Pharmaceuticals will post 13.44 earnings per share for the current fiscal year.
In other news, Director Catherine A. Sohn sold 726 shares of the business’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $135.65, for a total transaction of $98,481.90. Following the sale, the director now directly owns 9,574 shares of the company’s stock, valued at $1,298,713.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paul Treacy sold 4,371 shares of the business’s stock in a transaction on Monday, August 12th. The stock was sold at an average price of $137.40, for a total value of $600,575.40. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by insiders.
Several institutional investors have recently made changes to their positions in JAZZ. Machina Capital S.A.S. acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth $29,000. Signaturefd LLC raised its position in shares of Jazz Pharmaceuticals by 56.3% during the second quarter. Signaturefd LLC now owns 200 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 72 shares during the period. Captrust Financial Advisors raised its position in shares of Jazz Pharmaceuticals by 120.0% during the second quarter. Captrust Financial Advisors now owns 220 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 120 shares during the period. Stonebridge Capital Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth $37,000. Finally, Clear Perspective Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth $81,000. 87.62% of the stock is currently owned by institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Further Reading: Quantitative Easing
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.